Clinical trials for preventative HIV gel

By Bizclik Editor

 

Scientists in South Africa are holding clinical trials to test a gel they believe could reduce the risk of women being infected with HIV.

The gel is being tested at seven centres and according to Professor Helen Rees, Executive Director of the Wits Reproductive Health and HIV Institute, is the first South African team of scientists to head a multi-site trial.

Previously, multi-site trials were led by international scientists working with local peers.

 

READ MORE FROM THE WDM CONTENT NETWORK:

To read the latest edition of African Business Review, click here.

 

"The planning for the Facts study is well under way and we hope to be in the field by August," said Rees.

The Tenofovir vaginal gel is seen as a positive breakthrough for HIV prevention. It proved 39 percent effective at protecting young women from HIV and halved the risk of Herpes HSV-2, according to the Caprisa 004 study in KwaZulu-Natal.

The Facts study aims to confirm these results.

Share

Featured Articles

Musk’s multibillion hostile Twitter takeover – the timeline

As billionaire entrepreneur Elon Musk buys Twitter for US$44bn, we draw up a timeline, from the buying of shares to the critical tweets and unsolicited bid

Sustainable moves businesses can make to win customers, IBM

With half of consumers saying environmental sustainability is more important today than a year ago, businesses should up their eco action, says IBM report

Banks and consultancies top workplaces to grow career in UK

Financial and professional services firms rank highest in LinkedIn Top 25 best workplaces list – from Barclays, Lloyds and HSBC, to PwC, Deloitte and EY

Top 10 women in technology in Europe

Leadership & Strategy

The value of ESG links sustainability to business returns

Sustainability

Top 10 European football clubs by revenue 2022 – Deloitte

Corporate Finance